|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_ocn964295387 |
| 003 |
OCoLC |
| 005 |
20231120112155.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
161125t20162017enk o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d N$T
|d IDEBK
|d EBLCP
|d OPELS
|d OCLCQ
|d N$T
|d OCLCA
|d OCLCO
|d OCLCQ
|d OTZ
|d OCLCQ
|d YDX
|d OCLCO
|d OCLCA
|d U3W
|d MERUC
|d OCLCO
|d D6H
|d OCLCO
|d OCLCF
|d OCLCO
|d CHVBK
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCA
|d OCLCQ
|d S2H
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 963932038
|a 967057282
|
| 020 |
|
|
|a 9780128054314
|q (electronic bk.)
|
| 020 |
|
|
|a 012805431X
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128052747
|
| 020 |
|
|
|z 0128052740
|
| 035 |
|
|
|a (OCoLC)964295387
|z (OCoLC)963932038
|z (OCoLC)967057282
|
| 050 |
|
4 |
|a RM302.5
|
| 060 |
|
4 |
|a WA 950
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.7/042
|2 23
|
| 100 |
1 |
|
|a Pal, Ranadip,
|e author.
|
| 245 |
1 |
0 |
|a Predictive modeling of drug sensitivity /
|c Ranadip Pal.
|
| 260 |
|
|
|a London, United Kingdom :
|b Academic Press,
|c [2016], �2017.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Front Cover; Predictive Modeling of Drug Sensitivity; Copyright; Contents; Preface; Chapter 1: Introduction; 1.1 Cancer Statistics; 1.2 Promise of Targeted Therapies; 1.3 Market Trends; 1.3.1 Biomarker Testing; 1.3.2 Pharmaceutical Solutions; 1.3.3 Value-Driven Outcomes; 1.4 Roadblocks to Success; 1.4.1 Linking Patient-Specific Traits to Efficacious Therapy; 1.4.2 High Costs of Targeted Therapies; 1.4.3 Resistance to Therapies; 1.4.4 Personalized Combination Therapy Clinical Trials; 1.5 Overview of Research Directions; References; Chapter 2: Data characterization; 2.1 Introduction.
|
| 505 |
8 |
|
|a 2.2 Review of Molecular BiologyTranslation; Mutation; 2.3 Genomic Characterizations; 2.3.1 DNA Level; 2.3.2 Epigenetic Level; 2.3.3 Transcriptomic Level; 2.3.4 Proteome Level; 2.3.5 Metabolome Level; 2.3.6 Missing Value Estimation; 2.4 Pharmacology; 2.4.1 Pharmacokinetics; 2.4.2 Pharmacodynamics; 2.4.2.1 Modeling techniques; Indirect response models; 2.4.3 Software Packages; 2.4.4 Drug Toxicity; 2.5 Functional Characterizations; 2.5.1 Cell Viability Measurements; 2.5.2 Drug Characterizations; References; Chapter 3: Feature selection and extraction from heterogeneous genomic characterizations.
|
| 505 |
8 |
|
|a 3.1 Introduction3.2 Data-Driven Feature Selection; 3.2.1 Filter Techniques; 3.2.1.1 Relief; Example to illustrate Relief; 3.2.1.2 Relief-F; 3.2.1.3 R-Relief-F; Example to illustrate regression ReliefF; 3.2.2 Wrapper Techniques; 3.2.2.1 Sequential forward search; 3.2.2.2 Sequential floating forward search; Example to illustrate SFFS; 3.3 Data-Driven Feature Extraction; 3.3.1 Principal Component Analysis; Example to illustrate PCA; 3.4 Multiomics Feature Extraction and Selection; 3.4.1 Category 1: Union of Transcriptomic and Proteomic Data.
|
| 505 |
8 |
|
|a 3.4.2 Category 2: Extraction of Common Functional Context of Transcriptomic and Proteomic Features3.4.3 Category 3: Topological Network-Based Techniques; 3.4.4 Category 4: Missing Value Estimation of Proteomic Data Based on Nonlinear Optimization; 3.4.5 Category 5: Multiple Regression Analysis to Predict Contribution of Sequence Features in mRNA-Protein Correlation; 3.4.6 Category 6: Clustering-Based Techniques; 3.4.7 Category 7: Dynamic Modeling; References; Chapter 4: Validation methodologies; 4.1 Introduction; 4.1.1 Model Evaluation; 4.2 Fitness Measures; Data Representation.
|
| 505 |
8 |
|
|a 4.2.1 Norm-Based Fitness Measures4.2.2 Correlation Coefficient; 4.2.3 Coefficient of Determination R2; 4.2.4 Akaike Information Criterion; 4.3 Sample Selection Techniques for Accuracy Estimation; 4.3.1 Resubstitution or Training Error; 4.3.2 Hold Out; 4.3.3 K-Fold Cross Validation; 4.3.4 Bootstrap; 4.3.5 Confidence Interval; 4.4 Small Sample Issues; 4.4.1 Simulation Study; 4.4.1.1 NCI-DREAM drug sensitivity dataset; 4.4.1.2 CCLE dataset; 4.4.1.3 Bias correction; 4.5 Experimental Validation Techniques; 4.5.1 In Vitro Cell Lines; 4.5.2 In Vitro Primary Tumor Cultures.
|
| 500 |
|
|
|a Includes index.
|
| 650 |
|
0 |
|a Drugs
|x Side effects
|x Statistical methods.
|
| 650 |
|
0 |
|a Drugs
|x Mathematical models.
|
| 650 |
|
0 |
|a Pharmacology
|x Mathematical models.
|
| 650 |
|
0 |
|a Drug resistance.
|
| 650 |
|
2 |
|a Models, Statistical
|0 (DNLM)D015233
|
| 650 |
|
2 |
|a Drug Resistance
|0 (DNLM)D004351
|
| 650 |
|
6 |
|a M�edicaments
|0 (CaQQLa)201-0002241
|x Effets secondaires
|0 (CaQQLa)201-0002241
|x M�ethodes statistiques.
|0 (CaQQLa)201-0373903
|
| 650 |
|
6 |
|a M�edicaments
|0 (CaQQLa)201-0002990
|x Mod�eles math�ematiques.
|0 (CaQQLa)201-0379082
|
| 650 |
|
6 |
|a Pharmacologie
|0 (CaQQLa)201-0007219
|x Mod�eles math�ematiques.
|0 (CaQQLa)201-0379082
|
| 650 |
|
6 |
|a R�esistance aux m�edicaments.
|0 (CaQQLa)201-0079541
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Drug resistance
|2 fast
|0 (OCoLC)fst00898701
|
| 650 |
|
7 |
|a Drugs
|x Mathematical models
|2 fast
|0 (OCoLC)fst00898842
|
| 776 |
0 |
8 |
|i Print version:
|a Pal, Ranadip.
|t Predictive modeling of drug sensitivity.
|d London, United Kingdom : Academic Press, [2016], �2017
|z 9780128052747
|z 0128052740
|w (OCoLC)952982938
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128052747
|z Texto completo
|
